Who is sponsoring NCT05310838?

NCT05310838 is sponsored by California State University, San Bernardino.

What drugs are being tested in NCT05310838?

Interventions in NCT05310838: Behavioral Activation for First Episode Psychosis, Treatment As Usual.

What condition does NCT05310838 study?

NCT05310838 studies Engagement, Patient, First Episode Psychosis.

Is NCT05310838 still recruiting?

NCT05310838 is currently active, enrolled. Last updated 18 March 2026.

Last reviewed 2026-03-18 · How we verify

NCT05310838

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Optimizing Engagement in Services for First-Episode Psychosis

Active, enrolled NA Last updated 18 March 2026

What this trial tests

NA trial testing Behavioral Activation for First Episode Psychosis in Engagement, Patient in 58 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 March 2022

Primary endpoint
16 December 2025

30 June 2026

Quick facts

Lead sponsor	California State University, San Bernardino
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	58
Start date	1 March 2022
Primary completion	16 December 2025
Estimated completion	30 June 2026
Sites	2 locations across United States

Drugs / interventions tested

Behavioral Activation for First Episode Psychosis
Treatment As Usual

Conditions studied

Engagement, Patient — all drugs for Engagement, Patient →
First Episode Psychosis — all drugs for First Episode Psychosis →

Sponsor

California State University, San Bernardino

Who can join

Adults 15 to 35, any sex, with Engagement, Patient or First Episode Psychosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will compare a 12-session behavioral activation (BA) intervention modified for first-episode psychosis (FEP) to usual community mental health care (i.e., treatment-as-usual; TAU) delivered over 6 months with a sample of Latinos with FEP and their families. Comparable family group sessions will also be delivered to participants in both conditions. It is expected that BA participants will show better engagement than TAU participants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Engagement, Patient

Currently open trials in the same condition.

NCT07489105 — Forge AHEAD: Feasibility of Yoga to Improve Cognitive Function · NA · recruiting
NCT06410508 — Evaluation of a Brief Intervention to Improve Engagement in Early Intervention Services for Psychosis · NA · recruiting
NCT06575582 — Digital Navigators for Acceptance and Competence Development with Mental Health Apps · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05310838 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by California State University, San Bernardino
Last refreshed: 18 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05310838.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing